NCT00146003 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

Efalizumab for Eczema


Sponsors: University of Medicine and Dentistry New Jersey Genentech	Phases: Phase II
Indications	Acronym:
Dermatitis, Atopic
Age Groups: Adult Senior	Gender: Both
Names: Drug: Efalizumab treatment	Enrollment: 10

Additional information about NCT00146003.